Showing results (761-770 of 828) with videos related to

Sort By:
Pageof 83
American Journal of Physiology. Cell Physiology|January 20, 2018
Acute and chronic resistance training downregulates select LINE-1 retrotransposon activity markers in human skeletal muscleMatthew A Romero, C Brooks Mobley, Petey W Mumford, et al.
Frontiers in Chemical Biology|April 20, 2026
Development of SYK NanoBRET cellular target engagement assays for gain-of-function variantsJacob L Capener, James D Vasta, Vittorio L Katis, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Development of SYK NanoBRET Cellular Target Engagement Assays for Gain-of-Function VariantsJacob L Capener, James D Vasta, Vittorio L Katis, et al.
Physical Review Letters|March 13, 2026
Detailed View at Magnetic Dipole Strengths: The Case of Semimagic ^{50}TiB Kelly, M Spieker, U Friman-Gayer, et al.
Steroids|June 15, 2014
Transcriptional regulation of myotrophic actions by testosterone and trenbolone on androgen-responsive muscleFan Ye, Sean C McCoy, Heather H Ross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2014
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapyCristina Saura, Johanna Bendell, Guy Jerusalem, et al.
Breast (Edinburgh, Scotland)|June 24, 2016
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity studyG Curigliano, P Gómez Pardo, F Meric-Bernstam, et al.
Geroscience|December 17, 2025
Beyond strength: dietary nitrate augments self-selected functional mobility after resistance training in middle-aged adultsBrandon M Peoples, Mason C McIntosh, Kenneth D Harrison, et al.
Cell Chemical Biology|July 25, 2023
DELs enable the development of BRET probes for target engagement studies in cellsKelly A Teske, Wenji Su, Cesear R Corona, et al.
ESMO Open|June 28, 2023
Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trialJ Rodon Ahnert, D S-W Tan, I Garrido-Laguna, et al.
Pageof 83